Heron Therapeutics | ARS: Annual Report to Security Holders
Heron Therapeutics | DEF 14A: Definitive information statements
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Duarte Ira
Heron Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forbes William P
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Collard Craig A
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Collard Craig A
Heron Therapeutics | 8-K: Current report
Heron Therapeutics | 10-K: Annual report
Heron Therapeutics | 8-K: Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Baker Bros. Advisors LP(4.99%),Baker Bros. Advisors (GP) LLC(4.99%), etc.
Heron Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Great Point Partners, LLC(0%),Dr. Jeffrey R. Jay, M.D.(0%), etc.
Heron Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(0%),Deep Track Biotechnology Master Fund, Ltd.(0%), etc.
Heron Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.56%)
Heron Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Franklin Resources, Inc.(4.3%)
Heron Therapeutics | 8-K: Current report
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Christian Waage
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Rodriguez Susan
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Morgan Adam
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Johnson Craig A
No Data